Trump Impact on Medicare Drug Price Negotiations Uncertain
Trump has reversed some of President Biden’s initiatives, including $2 monthly out-of-pocket cap on some generics and experimental pricing models for gene therapies. But so far the healthcare elements of the Inflation Reduction Act remain unchanged.
Funding cuts and regulatory changes could radically reduce Medicaid, the largest program providing medical and health-related ...
The new Trump administration should seize the opportunity to change the Medicare drug price negotiation program by ...
Transparency in the program is more than just a mechanism for fair pricing—it is a driving force that diminishes the returns ...
Donald Trump has rescinded an executive order from President Joe Biden that sought to lower the price of drugs.
In November, a federal judge ordered CMS to recalculate UnitedHealthcare's Medicare Advantage Star Ratings for the 2025 plan ...
Final rule makes it easier for CMS to suspend agents and brokers who exchange plans without notifying the Medicare customer.
The Centers for Medicare and Medicaid Services (CMS) has included Ozempic among the next 15 drugs chosen for Medicare ...
Federal health agencies, including the Centers for Medicare & Medicaid Services, have halted their communication efforts in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback